2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

4:30PM-6:00PM: Abstract Number: 2853

Is Frailty Associated with Adverse Events after Total Joint Arthroplasty?

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2850

Jakinibs Decrease Chronic Low Back Pain and Increase Function: A Proof of Concept Trial

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2887

Long-Term Follow-up Report on Japanese Patients with Severe Systemic Sclerosis after Autologous Hematopoietic Stem Cell Transplantation

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics II

4:30PM-6:00PM: Abstract Number: 2866

Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2875

Molecular Features Define Unique Sjögren’s Syndrome Patient Subsets

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

4:30PM-6:00PM: Abstract Number: 2854

Optimizing Data Capture for Performance – Metrics Using Smartphone App Technology

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2849

Pain and Functional Trajectories in Symptomatic Knee Osteoarthritis over a 12-Week Period of Non-Pharmacological Exercise Interventions

Orthopedics, Low Back Pain and Rehabilitation

4:30PM-6:00PM: Abstract Number: 2868

Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy IV: Pharmacodynamic Markers and Therapeutic Intervention

4:30PM-6:00PM: Abstract Number: 2839

Practice Patterns of Pneumocystis Pneumonia Prophylaxis in Connective Tissue Diseases: a Survey of Infectious Disease Physicians

Infection-related Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2881

Pre-Existing Psoriasis Is Predictive for Clinical Relapse after Drug-Free Remission Induced By Therapy with Golimumab in Early Peripheral Spondyloarthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2823

Preliminary Comparison of Patient-Centered Weight Loss Programs Starting before Versus after Knee Replacement

ARHP: Exemplary Abstracts

4:30PM-6:00PM: Abstract Number: 2877

Premature Senescence of Naive CD4+ T-Cells in Primary Sjogren’s Syndrome

Sjögren's Syndrome II: Pathogenesis, Autoantibodies and T-Cells

4:30PM-6:00PM: Abstract Number: 2883

Prevalence of Cardiovascular Risk Factors and Subclinical Cardovacular Disease in Psoriatic Arthritis

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment IV

4:30PM-6:00PM: Abstract Number: 2831

Real-World Experience with Tofacitinib Versus Adalimumab and Etanercept in Biologic-Naive Patients with RA Previously Treated with Methotrexate: Data from a US Administrative Healthcare Insurance Claims Database

Health Services Research I: Cost Drivers in Rheumatic Disease

4:30PM-6:00PM: Abstract Number: 2844

Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study

Metabolic and Crystal Arthropathies I: Gout Risk of Disease Activity, Cardiovascular Disease and Mortality

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].